ABOUT US
Accro Bioscience was established by a group of industrial veterans and scientists with decades of experience in drug research and development in 2017. Accro Bioscienceis a clinical stage biotech company with the core focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases.
Harnessing the power of disease biology and drug discovery, Accrohas developed a robust portfolio of innovative compounds in various stages spanning from lead optimization to clinical trials.The company's RIPK1 inhibitor AC-003 was approved for clinical trialby FDA and NMPA in December 2021 and August 2022, respectively. AC-003 has completed the Phase I clinical trial inChina and the United States in August 2023 and achieved positive results, and the clinical trial for aGvHD patients is currently undergoing. The Company’s RIKP2 inhibitor AC-101 was approved by HREC in March 2023 for clinical trial.It has completedthe Phase I clinical trial in Australiademonstratingan outstanding safety and PK/PD profile. AC-201, a selective TYK2/JAK1 inhibitor with "Pipeline-in-a-Product" potential for treating inflammatory and autoimmune diseases, was approved by HREC and NMPA in May 2023 and September 2023.It has completedthe Phase I trial in Australiaand China, and is currently in Phase II clinical trial for patients with moderate to severe plaque psoriasis. The Company has multiple compounds in the PCC and preclinical research stages. The Company owns global rights of all its assets with more than 10 patents issued in major markets includingthe US, the EU, China, Japan, and Korea.
-
Vision
Be the guardian of your health and a world’s therapeutic leader in where we focus
-
Mission
Driven by Science and discovery, develop novel therapies to meet unfulfilled health needs in inflammation, autoimmune diseases and cancer
-
Value
People, Interity, Dedication, Innovation
-
R&D TALENT POOL
The core R&D team is made of industrial and academic experts in molecular mechanisms of regulated cell death and related pathogenesis in human diseases. In its journey toward developing innovative medicines, the Company has also recruited a number of industrial veterans in Medicinal Chemistry, Pharmacology, Toxicology, DMPK, CMC, Clinical Studies, etc.
-
SCIENCE AND PUBLICATIONS
Cell death programs are critical for the maintenance of organismal homeostasis and the control of immune responses. Regulated cell death such as necroptosis, pyroptosis, and ferroptosis are associated with many major human diseases . Focusing on molecular targets associated with regulated cell death, Accro Bioscience (Suzhou) Limited has developed multiple innovative compounds for therapeutic intervention of inflammatory and autoimmune diseases and cancer.
-
PIPELINE
The company has a robust drug discovery portfolio with innovative compounds in various stages spanning from lead optimization to pre-clinical development.
-
06
2024-05
Accropeutics doses TYK2/JAK1 inhibitor AC-201 in Psoriasis Patient in ChinaMORE > -
29
2024-04
Accropeutics Bioscience Announces Positive Results from its Phase I Clinical Trial Evaluating RIPK2 Kinase Inhibitor AC-101 in Healthy Human Subjects in AustraliaMORE > -
25
2023-12
Accropeutics' RIPK1 inhibitor AC-003 capsule has been granted Orphan Drug Designation by the FDAMORE > -
09
2023-09
Selective TYK2/JAK1 Inhibitor AC-201 gained National Medical Products Administration (NMPA) permission for Phase 1MORE >